Thus, the NRF2 under-expression observed in this study could make cancer cells more responsive to antineoplastic agents, considering that high NRF2 expression is associated with HT-29 cells resistant to chemotherapeutic agents routinely used in CRC treatment (18). Here, NFE2L2 is linked to colorectal carcinoma.